Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception
Low/intermediate doses of enzalutamide show comparable efficacy than high dose while improving tolerability, indicating the need for further search of its optimal dose. Moreover, our findings prompt a study of the optimal dose in advanced disease and in the prevention/interception setting in patients with low/intermediate risk PCa under active surveillance.
Authors
- Matteo Puntoni (ORCID: https://orcid.org/0000-0002-7908-0626)
- Carlotta Defferrari
- Davide Corradengo
- F. Germinale (ORCID: https://orcid.org/0000-0001-7680-0993)
- Marco Ennas
- Alberto Gozza
- Mauro D’Amico (ORCID: https://orcid.org/0000-0001-5821-3410)
- Matteo Clavarezza
- Tania Buttiron Webber (ORCID: https://orcid.org/0000-0002-3605-2828)
- Carlo Introini (ORCID: https://orcid.org/0000-0002-7746-9291)
- Howard L. Parnes (ORCID: https://orcid.org/0000-0003-3401-0007)
- Irene Maria Briata (ORCID: https://orcid.org/0000-0003-0767-0026)
- Nicoletta Provinciali (ORCID: https://orcid.org/0000-0002-7803-3852)
- Andrea DeCensi (ORCID: https://orcid.org/0000-0003-2635-4491)
- Martino Oliva
- Alessio Carbone (ORCID: https://orcid.org/0009-0008-9907-3299)
- Monica Boitano
Institutions
- University of Parma (IT)
- Ente Ospedaliero Ospedali Galliera (IT)
- National Cancer Institute (US)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1186/s12885-025-15396-y
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00